Shigellosis: Innate Mechanisms of Inflammatory Destruction of the Intestinal Epithelium, Adaptive Immune Response, and Vaccine Development

Critical Reviews in Immunology

Volumn 23, Issue 5-6, 2003, Pages 371-401

  Phalipon, Armelle ^a   Sansonetti, P J ^a  

^a INSERM   (France)

Author keywords

Host pathogen cross talk; Invasive enterobacterium; Mucosal immunity

Indexed keywords

BACTERIAL PROTEIN; BACTERIUM LIPOPOLYSACCHARIDE; CD14 ANTIGEN; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIVE VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRALIZING ANTIBODY; PLASMID DNA; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SC 602; SECRETORY IMMUNOGLOBULIN; SHIGELLA VACCINE; SYNTHETIC PEPTIDE; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL CRAMP; ADULT; ANIMAL MODEL; ANTIBODY RESPONSE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIAL MEMBRANE; BACTERIAL VIRULENCE; CHILD; CLINICAL TRIAL; COLONY FORMING UNIT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DENDRITIC CELL; DIARRHEA; DOUBLE BLIND PROCEDURE; ENTERITIS; FEVER; GRAM NEGATIVE INFECTION; HEADACHE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INFLAMMATION; INTESTINE EPITHELIUM; KNOCKOUT MOUSE; MACROPHAGE; MONOCYTE; MOUSE; MUCOSAL IMMUNITY; NEUTROPHIL; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RABBIT; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEROTYPE; SHIGELLA; SHIGELLA DYSENTERIAE; SHIGELLA FLEXNERI; SHIGELLA SONNEI; SHIGELLOSIS; SIDE EFFECT; TH1 CELL; TH2 CELL; ULCERATIVE COLITIS; VACCINATION;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; BACTERIAL PROTEINS; DENDRITIC CELLS; DYSENTERY, BACILLARY; EPITHELIAL CELLS; HUMANS; IMMUNITY, MUCOSAL; IMMUNITY, NATURAL; INTESTINES; MACROPHAGES; SHIGELLA; SHIGELLA VACCINES;

EID: 1242291784     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevImmunol.v23.i56.20     Document Type: Review

References (256)

1. Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD, Swerdlow DL, Sansonetti PJ, Adak GK, Levine MM. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull WHO 1999; 77:651-666.
2. DuPont HL, Levine MM, Hornick RB, Formal SB. Inoculum size in shigellosis and implications for expected mode of transmission. J Infect Dis 1989; 159: 1126-1128.
3. Wassef JS, Keren DK, Mailloux JM. Role of M cell in initial uptake and in ulcer formation in the rabbit intestinal loop model of shigellosis. Infect Immun 1989; 57:858-863.
4. Mathan MM, Mathan VI. Morphology of rectal mucosa of patients with shigellosis. Rev Infect Dis 1991; 13:S314-S318.
5. Speelman P, Kabir I, Islam M. Distribution and spread of colonic lesions in shigellosis: a colonoscopic study. J Infect Dis 1984; 150:899-903.
6. Sansonetti PJ. Molecular mechanisms of cell and tissue invasion by Shigella flexneri. Infect Agents Dis 1993; 2:201-206.
7. Sansonetti PJ, Kopecko DJ, Formal SB. Involvement of a plasmid in the invasive ability of Shigella flexneri. Infect Immun 1982; 35:852-860.
8. Sansonetti PJ, Hale TL, Dammin GJ, Kapfer C, Collins HH Jr, Formal SB. Alterations in the pathogenicity of Escherichia coli K-12 after transfer of plasmid and chromosomal genes from Shigella flexneri. Infect Immun 1983; 39:1392-402.
9. Buchrieser C, Glaser P, Rusniok C, Nedjari H, d'Hauteville H, Kunst F, Sansonetti PJ, Parsot C. The virulence plasmid pWR100 and the repertoire of proteins secreted by the type III secretion apparatus of Shigella flexneri. Mol Microbiol 2000; 38: 760-771.
10. Mounier J, Vasselon T, Hellio R, Lesourd M, Sansonetti PJ. Shigella flexneri enters human colonic Caco-2 epithelial cells through the basolateral pole. Infect Immun 1992; 60:237-248.
11. Sansonetti PJ, Arondel J, Cantey JR, Prevost MC, Huerre M. Infection of rabbit Peyer's patches by Shigella flexneri: effect of adhesive or invasive bacterial phenotypes on follicle-associated epithelium. Infect Immun 1996; 64(7):2752-2764.
12. Perdomo OJ, Cavaillon JM, Huerre M, Ohayon H, Gounon P, Sansonetti PJ. Acute inflammation causes epithelial invasion and mucosal destruction in experimental shigellosis. J Exp Med 1994; 180:1307-1319.
13. Kato J, Ito K, Nakamura A, Watanabe H. Cloning of regions required for contact hemolysis and entry into LLC-MK2 cells from Shigella sonnei form I plasmid: virF is a positive regulator gene for these phenotypes. Infect Immun 1989; 57:1391-1398.
14. Maurelli AT, Baudry B, d'Hauteville H, Hale TL, Sansonetti PJ. Cloning of plasmid DNA sequences involved in invasion of HeLa cells by Shigella flexneri. Infect Immun 1985; 49:164-171.
15. Sasakawa C, Kamata K, Sakai T, Makino S, Yamada M, Okada N, Yoshikawa M. Virulence-associated genetic regions comprising 31 kilobases of the 230-kilobase plasmid in Shigella flexneri 2a. J Bacteriol 1988; 170:2480-2484.
16. Sasakawa C, Komatsu K, Tobe T, Suzuki T, Yoshikawa M. Eight genes in region 5 that form an operon are essential for invasion of epithelial cells by Shigella flexneri 2a. J Bacteriol 1993; 175:2334-2346.
17. Sasakawa C, Makino S, Kamata K, Yoshikawa M. Isolation, characterization, and mapping of Tn5 insertions into the 140-megadalton invasion plasmid defective in the mouse Sereny test in Shigella flexneri 2a. Infect Immun 1986; 54:32-36.
18. Adler B, Sasakawa C, Tobe T, Makino S, Komatsu K, Yoshikawa M. A dual transcriptional activation system for the 230 kb plasmid genes coding for virulence-associated antigens of Shigella flexneri. Mol Microbiol 1989; 3:627-635.
19. Galan JE, Collmer A. Type III secretion machines: bacterial devices for protein delivery into host cells. Science 1999; 284:1322-1328.
20. Kubori T, Matsushima Y, Nakamura D, Uralil J, Lara-Tejero M, Sukhan A, Galan JE, Aizawa SI. Supramolecular structure of the Salmonella typhimurium type III protein secretion system. Science 1998; 280: 602-605.
21. Blocker A, Gounon P, Larquet E, Niebuhr K, Cabiaux V, Parsot C, Sansonetti PJ. The tripartite type III secreton of Shigella flexneri inserts IpaB and IpaC into host membranes. J Cell Biol 1999; 147:683-693.
22. Blocker A, Jouihri N, Larquet E, Gounon P, Ebel F, Parsot C, Sansonetti PJ, Allaoui A. Structure and composition of the Shigella flexneri "needle complex", a part of its type III secreton. Mol Microbiol 2001; 39:652-663.
23. Allaoui A, Sansonetti PJ, Ménard R, Barzu S, Mounier J, Phalipon A, Parsot C. MxiG, a membrane protein required for secretion of Shigella spp. Ipa invasins: involvement in entry into epithelial cells and in intercellular dissemination. Mol Microbiol 1995; 17:461-470.
24. Parsot C, Ménard R, Gounon P, Sansonetti PJ. Enhanced secretion through the Shigella flexneri Mxi-Spa translocon leads to assembly of extracellular proteins into macromolecular structures. Mol Microbiol 1995; 16:291-300.
25. Schuch R, Maurelli AT. The mxi-Spa type III secretory pathway of Shigella flexneri requires an outer membrane lipoprotein, MxiM, for invasin translocation. Infect Immun 1999; 67:1982-1991.
26. Schuch R, Maurelli AT. MxiM and MxiJ, base elements of the Mxi-Spa type III secretion system of Shigella, interact with and stabilize the MxiD secretin in the cell envelope. J Bacteriol 2001; 183:6991-6998.
27. Tamano K, Aizawa S, Katayama E, Nonaka T, Imajoh-Ohmi S, Kuwae A, Nagai S, Sasakawa C. Supramolecular structure of the Shigella type III secretion machinery: the needle part is changeable in length and essential for delivery of effectors. EMBO J 2002; 19: 3876-3887.
28. Tamano K, Katayama E, Toyotome T, Sasakawa C. Shigella Spa32 is an essential secretory protein for functional type III secretion machinery and uniformity of its needle length. J Bacteriol 2002; 184(5): 1244-1252.
29. Wattiau P, Bernier B, Deslee P, Michiels T, Cornelis GR. Individual chaperones required for Yop secretion by Yersinia. Proc Natl Acad Sci U S A 1994; 91: 10493-10497.
30. Wattiau P, Woestyn S, Cornelis GR. Customized secretion chaperones in pathogenic bacteria. Mol Microbiol 1996; 20:255-262.
31. Ménard R, Sansonetti PJ, Parsot C, Vasselon T. Extracellular association and cytoplasmic partitioning of the IpaB and IpaC invasins of S. flexneri. Cell 1994; 79:515-525.
32. Niebuhr K, Jouihri N, Allaoui A, Gounon P, Sansonetti PJ, Parsot C. IpgD, a protein secreted by the type III secretion machinery of Shigella flexneri, is chaperoned by IpgE and implicated in entry focus formation. Mol Microbiol 2000; 38:8-19.
33. Page AL, Sansonetti PJ, Parsot C. Spa15 of Shigella flexneri, a third type of chaperone in the type III secretion pathway. Mol Microbiol 2002; 43: 1533-1542.
34. Bahrani FK, Sansonetti PJ, Parsot C. Secretion of Ipa proteins by Shigella flexneri: inducer molecules and kinetics of activation. Infect Immun 1997; 65: 4005-4010.
35. Ménard R, Sansonetti PJ, Parsot C. Nonpolar mutagenesis of the ipa genes defines IpaB, IpaC, and IpaD as effectors of Shigella flexneri entry into epithelial cells. J Bacteriol 1993; 175:5899-5906.
36. Parsot C, Ménard R, Gounon P, Sansonetti PJ. Enhanced secretion through the Shigella flexneri Mxi-Spa translocon leads to assembly of extracellular proteins into macromolecular structures. Mol Microbiol 1995; 16:291-300.
37. Adam T, Arpin M, Prévost MC, Gounon P, Sansonetti PJ. Cytoskeletal rearrangements and the functional role of T-plastin during entry of Shigella flexneri into HeLa cells. J Cell Biol 1995; 129:367-381.
38. Watarai M, Funato S, Sasakawa C. Interaction of Ipa proteins of Shigella flexneri with alpha5beta1 integrin promotes entry of the bacteria into mammalian cells. J Exp Med 1996; 183:991-999.
39. Skoudy A, Mounier J, Aruffo A, Ohayon H, Gounon P, Sansonetti P, Tran Van Nhieu G. CD44 binds to the Shigella IpaB protein and participates in bacterial invasion of epithelial cells. Cell Microbiol 2000; 2:19-33.
40. Lafont F, Tran Van Nhieu G, Hanada K, Sansonetti P, van der Goot FG. Initial steps of Shigella infection depend on the cholesterol/sphingolipid raft-mediated CD44-IpaB interaction. EMBO J 2002; 21: 4449-4457.
41. Tran Van Nhieu G, Caron E, Hall A, Sansonetti PJ. IpaC induces actin polymerization and filopodia formation during Shigella entry into epithelial cells. EMBO J 1999; 18:3249-3262.
42. Davis R, Marquart ME, Lucius D, Picking WD. Protein-protein interactions in the assembly of Shigella flexneri invasion plasmid antigens IpaB and IpaC into protein complexes. Biochim Biophys Acta 1998; 1429:45-56.
43. Marquart ME, Picking WL, Picking WD. Soluble invasion plasmid antigen C (IpaC) from Shigella flexneri elicits epithelial cell responses related to pathogen invasion. Infect Immun 1996; 64:4182-4187.
44. Tran Van Nhieu G, Bourdet-Sicard R, Dumenil G, Blocker A, Sansonetti PJ. Bacterial signals and cell responses during Shigella entry into epithelial cells. Cell Microbiol 2000; 2:187-193.
45. Tran N, Serfis AB, Osiecki JC, Picking WL, Coye L, Davis R, Picking WD. Interaction of Shigella flexneri IpaC with model membranes correlates with effects on cultured cells. Infect Immun 2000; 68:3710-3715.
46. Picking WL, Coye L, Osiecki JC, Barnoski Serfis A, Schaper E, Picking WD. Identification of functional regions within invasion plasmid antigen C (IpaC) of Shigella flexneri. Mol Microbiol 2001; 39:100-111.
47. Adam T, Giry M, Boquet P, Sansonetti PJ. Rho-dependent membrane folding causes Shigella entry into epithelial cells. EMBO J 1996; 15:3315-3321.
48. Mounier J, Laurent V, Hall A, Fort P, Carlier M-F, Sansonetti PJ, Egile C. Rho family GTPases control entry of Shigella flexneri into epithelial cells but not intracellular motility. J Cell Sci 1999; 112:2069-2080.
49. Nobes CD, Hall A. Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell 1995; 81:53-62.
50. Dehio C, Prevost MC, Sansonetti PJ. Invasion of epithelial cells by Shigella flexneri induces tyrosine phosphorylation of cortactin by a pp60c-src-mediated signalling pathway. EMBO J 1995; 14:2471-2482.
51. Dumenil G, Olivo J-C, Pellegrini S, Fellous M, Sansonetti PJ, Tran Van Nhieu G. Interferon alpha inhibits a Src-mediated pathway necessary for Shigella-induced cytoskeletal rearrangements in epithelial cells. J Cell Biol 1998; 143:1003-1012.
52. Dumenil G, Sansonetti P, Tran Van Nhieu G. Src tyrosine kinase activity down-regulates Rho-dependent responses during Shigella entry into epithelial cells and stress fibre formation. J Cell Sci 2000; 113:71-80.
53. Skoudy A, Tran Van Nhieu G, Mantis N, Arpin M, Mounier J, Gounon P, Sansonetti PJ. A functional role for ezrin during Shigella flexneri entry into epithelial cells. J Cell Sci 1999; 112:2059-2068.
54. Niebuhr K, Giuriato S, Pedron T, Philpott DJ, Gaits F, Sable J, Sheetz MP, Parsot C, Sansonetti PJ, Payrastre B. Conversion of PtdIns(4,5)P(2) into PtdIns(5)P by the S.flexneri effector IpgD reorganizes host cell morphology. EMBO J 2002; 21:5069-5078.
55. Tran Van Nhieu G, Ben-Ze'ev A, Sansonetti PJ. Modulation of bacterial entry into epithelial cells by association between vinculin and the Shigella IpaA invasin. EMBO J 1997; 16:2717-2729.
56. Bourdet-Sicard R, Rudiger M, Jockusch BM, Gounon P, Sansonetti PJ, Tran Van Nhieu G. Binding of the Shigella protein IpaA to vinculin induces F-actin depolymerization. EMBO J 1999; 18:5853-5862.
57. Watarai M, Kamata Y, Kozaki S, Sasakawa C. Rho, a small GTP-binding protein, is essential for Shigella invasion of epithelial cells. J Exp Med 1997; 185: 281-292.
58. Bernardini ML, Mounier J, d'Hauteville H, Coquis-Rondon M, Sansonetti PJ. Identification of icsA, a plasmid locus of Shigella flexneri that governs bacterial intra- and intercellular spread through interaction with F-actin. Proc Natl Acad Sci U S A 1989; 86:3867-3871.
59. Makino S, Sasakawa C, Kamata K, Kurata T, Yoshikawa M. A genetic determinant required for continuous reinfection of adjacent cells on large plasmid in S. flexneri 2a. Cell 1986; 46:551-555.
60. d'Hauteville H, Dufourcq Lagelouse R, Nato F, Sansonetti PJ. Lack of cleavage of IcsA in Shigella flexneri causes aberrant movement and allows demonstration of a cross-reactive eukaryotic protein. Infect Immun 1996; 64:511-517.
61. Goldberg MB, Barzu O, Parsot C, Sansonetti PJ. Unipolar localization and ATPase activity of IcsA, a Shigella flexneri protein involved in intracellular movement. Infect Agents Dis 1993; 2:210-211.
62. Allaoui A, Mounier J, Prévost MC, Sansonetti PJ, Parsot C. icsB: a Shigella flexneri virulence gene necessary for the lysis of protrusions during intercellular spread. Mol Microbiol 1992; 6:1605-1616.
63. Sansonetti PJ, Tran Van Nhieu G, Egile C. Rupture of the intestinal epithelial barrier and mucosal invasion by Shigella flexneri. Clin Infect Dis 1999; 28:466-475.
64. Barzu S, Benjelloun-Touimi Z, Phalipon A, Sansonetti PJ, Parsot C. Functional analysis of the Shigella flexneri IpaC invasin by insertional mutagenesis. Infect Immun 1997; 65:1599-1605.
65. Egile C, Loisel TP, Laurent V, Li R, Pantaloni D, Sansonetti PJ, Carlier M-F. Activation of the CDC42 effector N-WASP by the Shigella flexneri IcsA protein promotes actin nucleation by Arp2/3 complex and bacterial actin-based motility. J Cell Biol 1999; 146: 1319-1332.
66. Goldberg MB, Theriot JA. Shigella flexneri surface protein IcsA is sufficient to direct actin-based motility. Proc Natl Acad Sci U S A 1995; 92:6572-6576.
67. Lett MC, Sasakawa C, Okada N, Sakai T, Makino S, Yamada M, Komatsu K, Yoshikawa M. virG, a plasmid-coded virulence gene of Shigella flexneri: identification of the VirG protein and determination of the complete coding sequence. J Bacteriol 1989; 171: 353-359.
68. Nakata N, Sasakawa C, Okada N, Tobe T, Fukuda I, Suzuki T, Komatsu K, Yoshikawa M. Identification and characterization of virK, a virulence-associated large plasmid gene essential for intercellular spreading of Shigella flexneri. Mol Microbiol 1992; 6:2387-2395.
69. Egile C, d'Hauteville H, Parsot C, Sansonetti PJ. SopA, the outer membrane protease responsible for polar localization of IcsA in Shigella flexneri. Mol Microbiol 1997; 23:1063-1073.
70. Steinhauer J, Agha R, Pham T, Varga AW, Goldberg MB. The unipolar Shigella surface protein IcsA is targeted directly to the bacterial old pole: IcsP cleavage of IcsA occurs over the entire bacterial surface. Mol Microbiol 1999; 32:367-377.
71. d'Hauteville H, Dufourcq Lagelouse R, Nato F, Sansonetti PJ. Lack of cleavage of IcsA in Shigella flexneri causes aberrant movement and allows demonstration of a cross-reactive eukaryotic protein. Infect Immun 1996; 64:511-517.
72. Robbins JR, Monack D, McCallun SJ, Vegas A, Pham E, Goldberg MB, Theriot JA. The making of a gradient: IcsA (VirG) polarity in Shigella flexneri. Mol Microbiol 2001; 41:861-872.
73. Radnedge L, Davis MA, Youngren B, Austin SJ. Plasmid maintenance functions of the large virulence plasmid of Shigella flexneri. J Bacteriol 1997; 179: 3670-3675.
74. Sandlin RC, Goldberg MB, Maurelli AT. Effect of O side-chain length and composition on the virulence of Shigella flexneri 2a. Mol Microbiol 1996; 22:63-73.
75. Sandlin RC, Lampel KA, Keasler SP, Goldberg MB, Stolzer AL, Maurelli AT. Avirulence of rough mutants of Shigella flexneri: requirement of O antigen for correct unipolar localization of IcsA in the bacterial outer membrane. Infect Immun 1995; 63:229-237.
76. Sandlin RC, Maurelli AT. Establishment of unipolar localization of IcsA in Shigella flexneri 2a is not dependent on virulence plasmid determinants. Infect Immun 1999; 67:350-356.
77. Suzuki T, Saga S, Sasakawa C. Functional analysis of Shigella VirG domains essential for interaction with vinculin and actin-based motility. J Biol Chem 1996; 271:21878-21885.
78. Suzuki T, Sasakawa C. N-WASP is an important protein for the actin-based motility of Shigella flexneri in the infected epithelial cells. Jpn J Med Sci Biol 1998; 51:S63-S68.
79. Goldberg MB. Shigella actin-based motility in the absence of vinculin. Cell Motil Cytoskeleton 1997; 37:44-53.
80. Laine RO, Zeile W, Kang F, Purich DL, Southwick FS. Vinculin proteolysis unmasks an Acta homolog for actin-based Shigella motility. J Cell Biol 1997; 138:1255-1264.
81. Suzuki T, Sasakawa C. Molecular basis of the intracellular spreading of Shigella. Infect Immun 2001; 69:5959-5966.
82. Miki H, Sasaki T, Takai Y, Takenawa T. Induction of filopodium formation by a WASP-related actin-depolymerizing protein N-WASP. Nature 1998; 391: 93-96.
83. Snapper SB, Takeshima F, Anton I, Liu CH, Thomas SM, Nguyen D, Dudley D, Fraser H, Purich D, Lopez-Ilasaca M, Klein C, Davidson L, Bronson R, Mulligan RC, Southwick F, Geha R, Goldberg MB, Rosen FS, Hartwig JH, Alt FW. N-WASP deficiency reveals distinct pathways for cell surface projections and microbial actin-based motility. Nat Cell Biol 2001; 3:897-904.
84. Suzuki T, Mimuro H, Miki H, Takenawa T, Sasaki T, Nakanishi H, Takai Y, Sasakawa C. Rho family GTPase Cdc42 is essential for the actin-based motility of Shigella in mammalian cells. J Exp Med 2000; 191:1905-1920.
85. Egile C, Sansonetti PJ. Manuscript in preparation.
86. Prévost MC, Lesourd M, Arpin M, Vernel F, Mounier J, Hellio R, Sansonetti PJ. Unipolar reorganization of F-actin layer at bacterial division and bundling of actin filaments by plastin correlate with movement of Shigella flexneri within HeLa cells. Infect Immun 1992; 60:4088-4099.
87. Sansonetti PJ, Mounier J, Prévost MC, Mège RM. Cadherin expression is required for the spread of Shigella flexneri between epithelial cells. Cell 1994; 76:829-839.
88. Vasselon T, Mounier J, Hellio R, Sansonetti PJ. Movement along actin filaments of the perijunctional area and de novo polymerization of cellular actin are required for Shigella flexneri colonization of epithelial Caco-2 cell monolayers. Infect Immun 1992; 60: 1031-1040.
89. Page AL, Ohayon H, Sansonetti PJ, Parsot C. The secreted IpaB and IpaC invasins and their cytoplasmic chaperone IpgC are required for intercellular dissemination of Shigella flexneri. Cell Microbiol 1999; 1:183-193.
90. Tran Van Nhieu G, Clair C, Bruzzone R, Mesnil M, Sansonetti PJ, Combettes L. Connexin-dependent intercell. Nat Cell Biol 2003; 5:720-726.
91. Zhang Z, Jin L, Champion G, Seydel KB, Stanley SL Jr. Shigella infection in a SCID mouse-human intestinal xenograft model: role for neutrophils in containing bacterial dissemination in human intestine. Infect Immun 2001; 69:3240-3247.
92. Formal SB, Kent TH, Austin S, Labrec EH. Fluorescent-antibody and histological study of vaccinated and control monkeys challenged with Shigella flexneri. J Bacteriol 1966; 91(6):2368-2376.
93. Keren DF, Scott PJ, Bauer D. Variables affecting the local immune response in Thiry-Vella loops. II. Stability of antigen-specific IgG and secretory IgA in acute and chronic Thiry-Vella loops. J Immunol 1980; 124(6):2620-2624.
94. Voino-Yasenetsky MV, Voino-Yasenetkaya MK. Experimental pneumonia caused by bacteria of the Shigella group. Acta Morpho 1961; XI:440-444.
95. Phalipon A, Kaufmann M, Michetti P, Cavaillon JM, Huerre M, Sansonetti P, Kraehenbuhl JP. Monoclonal immunoglobulin A antibody directed against serotype-specific epitope of Shigella flexneri lipopolysaccharide protects against murine experimental shigellosis. J Exp Med. 1995; 182(3):769-778.
96. Fernandez MI, Thuizat A, Pedron T, Neutra M, Phalipon A, Sansonetti PJ. A newborn mouse model for the study of intestinal pathogenesis of shigellosis. Cell Microbiol 2003; 5:481-491.
97. Raqib R, Lindberg AA, Wretlind B, Bardhan PK, Andersson U, Andersson J. Persistence of local cytokine production in shigellosis in acute and convalescent stages. Infect Immun 1995; 63:289-296.
98. Raqib R, Wretlind B, Andersson J, Lindberg AA. Cytokine secretion in acute shigellosis is correlated to disease activity and directed more to stool than to plasma. J Infect Dis 1995; 171:376-384.
99. Phalipon A, Sansonetti PJ. Microbial-host interactions at mucosal sites. Host response to pathogenic bacteria at mucosal sites. Curr Top Microbiol Immunol 1999; 236:163-189.
100. Clerc PL, Ryter A, Mounier J, Sansonetti PJ. Plasmid-mediated early killing of eukaryotic cells by Shigella flexneri as studied by infection of J774 macrophages. Infect Immun 1987; 55:521-527.
101. Zychlinsky A, Kenny B, Ménard R, Prévost MC, Holland IB, Sansonetti PJ. IpaB mediates macrophage apoptosis induced by Shigella flexneri. Mol Microbiol 1994; 11:619-627.
102. Hilbi H, Moss JE, Hersh D, Chen Y, Arondel J, Banerjee S, Flavell RA, Yuan J, Sansonetti PJ, Zychlinsky A. Shigella-induced apoptosis is dependent on caspase-1 which binds to IpaB. J Biol Chem 1998; 273:32895-32900.
103. Edgeworth JD, Spencer J, Phalipon A, Griffin GE, Sansonetti PJ. Cytotoxicity and interleukin-1beta processing following Shigella flexneri infection of human monocyte-derived dendritic cells. Eur J Immunol 2002; 32:1464-1471.
104. Zychlinsky A, Thirumalai K, Arondel J, Cantey JR, Aliprantis AO, Sansonetti PJ. In vivo apoptosis in Shigella flexneri infections. Infect Immun 1996; 64: 5357-5365.
105. Islam D, Veress B, Bardhan PK, Lindberg AA, Christensson B. In situ characterisation of inflammatory responses in the rectal mucosae of patients with shigellosis. Infect Immun 1997; 65:739-749.
106. Hilbi H, Puro RJ, Zychlinsky A. Tripeptidyl peptidase II promotes maturation of caspase-1 in Shigella flexneri-induced macrophage apoptosis. Infect Immun 2000; 68:5502-5508.
107. Zychlinsky A, Fitting C, Cavaillon JN, Sansonetti PJ. Interleukin 1 is released by macrophages during apoptosis induced by Shigella flexneri. J Clin Invest 1994; 94:1328-1332.
108. Arondel J, Singer M, Matsukawa A, Zychlinsky A, Sansonetti PJ. Increased interleukin-1 (IL-1) and imbalance between IL-1 and IL-1 receptor antagonist during acute inflammation in experimental shigellosis. Infect Immun 1999; 67:6056-6066.
109. Sansonetti PJ, Arondel J, Cavaillon JM, Huerre M. Role of IL-1 in the pathogenesis of experimental shigellosis. J Clin Invest 1995; 96:884-892.
110. Sansonetti PJ, Phalipon A, Arondel J, Thirumalai K, Banerjee S, Akira S, Takeda K, Zychlinsky A. Caspase-1 activation of IL-1beta and IL-18 are essential for Shigella flexneri-induced inflammation. Immunity 2000; 12:581-590.
111. Ozaki Y, Ohashi T, Minami A, Nakamura SI. Enhanced resistance of mice to bacterial infection induced by recombinant interleukin-1α. Infect Immun 1987; 55:1436-1440.
112. Pelkonen S, Pluschke G. Recombinant interleukin-1 stimulates clearance of Escherichia coli K1 bacteraemia. Microb Pathog 1989; 6:415-424.
113. Navarre WW, Zychlinsky A. Pathogen-induced apoptosis of macrophages: a common end for different pathogenic strategies. Cell Microbiol 2000; 2:265-273.
114. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science 1998; 281:1312-1316.
115. Lindberg AA, Karnell A, Weintraub A. The lipopolysaccharide of Shigella bacteria as a virulence factor. Rev Infect Dis 1991; 13(Suppl 4):S279-284.
116. DuPont HL, Hornick RB, Snyder MJ, Libonati JP, Formal SB, Gangarosa EJ. Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection. J Infect Dis 1972; 125:12-16.
117. d'Hauteville H, Khan S, Maskell DJ, Kussak A, Weintraub A, Mathison J, Ulevitch RJ, Wuscher N, Parsot C, Sansonetti PJ. Two msbB genes encoding maximal acylation of lipid A are required for invasive Shigella flexneri to mediate inflammatory rupture and destruction of the intestinal epithelium. J Immunol 2002; 168:5240-5251.
118. Beatty WL, Sansonetti PJ. Role of lipopolysaccharide in signaling to subepithelial polymorphonuclear leukocytes. Infect Immun 1997; 65:4395-4404.
119. Beatty WL, Méresse S, Gounon P, Davoust J, Mounier J, Sansonetti PJ, Gorvel JP. Trafficking of Shigella lipopolysaccharide in polarized intestinal epithelial cells. J Cell Biol 1999; 145:689-698.
120. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249:1431-1433.
121. Poltorak A, He X, Smimova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998; 282:2085-2088.
122. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999; 189:1777-1782.
123. Suzuki T, Hashimoto S, Toyoda N, Nagai S, Yamazaki N, Dong HY, Sakai J, Yamashita T, Nukiwa T, Matsushima K. Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE. Blood 2000; 96:2584-2591.
124. Anderson KV. Toll signaling pathways in the innate immune response. Curr Opin Immunol 2000; 12:13-19.
125. Abreu MT, Vora P, Faure E, Thomas LS, Arnold ET, Arditi, M. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol 2001; 167:1609-1616.
126. Elewaut D, DiDonato JA, Kim JM, Truong F, Eckmann L, Kagnoff MF. NF-κB is a central regulator of the intestinal epithelial cell innate response induced by infection with enteroinvasive bacteria. J Immunol 1999; 163:1457-1466.
127. Philpott DJ, Yamaoka S, Israel A, Sansonetti PJ. Invasive Shigella flexneri activates NF-kappa B through a lipopolysaccharide-dependent innate intracellular response and leads to IL-8 expression in epithelial cells. J Immunol 2000; 165:903-914.
128. Frevert CW, Matute-Bello G, Skerrett SJ, Goodman RB, Kajikawa O, Sittipunt C, Martin TR. Effect of CD14 blockade in rabbits with Escherichia coli pneumonia and sepsis. J Immunol 2000; 164:5439-5445.
129. Wenneras C, Ave P, Huerre M, Arondel J, Ulevitch RJ, Mathison JC, Sansonetti PJ. Blockade of CD14 increases Shigella-mediated invasion and tissue destruction. J Immunol 2000; 164:3214-3221.
130. McCormick BA, Hofman PM, Kim J, Carnes DK, Miller SI, Madara JL. Surface attachment of Salmonella typhimurium to intestinal epithelia imprints the subepithelial matrix with gradients chemotactic for neutrophils. J Cell Biol 1995; 131:1599-1608.
131. Girardin SE, Sansonetti PJ, Philpott DJ. Intracellular vs extracellular recognition of pathogens - common concepts in mammals and flies. Trends Microbiol 2002; 10:193-199.
132. Girardin SE, Tournebize R, Mavris M, Page AL, Li X, Stark GR, Bertin J, DiStefano PS, Yaniv M, Sansonetti PJ, Philpott DJ. Card4/Nod1 mediates NF-κB and JNK activation by invasive Shigella flexneri. EMBO Rep 2001; 2:736-742.
133. Girardin SE, Boneca IG, Carneiro LAM, Antignac A, Jéhanno M, Viala J, Tedin K, Taha MK, Labigne A, Zähringer U, Coyle AJ, DiStefano PS, Bertin P, Sansonetti PJ, Philpott DJ. Nod1 detects a unique muropeptide from Gram-negative bacterial peptidoglycan. Science 2003; 300:1584-1587.
134. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB. J Biol Chem 2001; 276:4812-4818.
135. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, Philpott DJ, Sansonetti PJ. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003; 278:8869-8872.
136. Perdomo JJ, Gounon P, Sansonetti PJ. Polymorphonuclear leukocyte transmigration promotes invasion of colonic epithelial monolayer by Shigella flexneri. J Clin Invest 1994; 93:633-643.
137. McCormick BA, Siber AM, Maurelli AT. Requirement of the Shigella flexneri virulence plasmid in the ability to induce trafficking of neutrophils across polarized monolayers of the intestinal epithelium. Infect Immun 1998; 66:4237-4243.
138. Pedron T, Thibault C, Sansonetti PJ. The invasive phenotype of Shigella flexneri causes a characteristic pattern of gene transcription in the human intestinal epithelial cell line Caco-2. J Biol Chem 2003; 278: 33878-33886.
139. Sansonetti PJ, Arondel J, Huerre M, Harada A, Matsushima K. Interleukin-8 controls bacterial transepithelial translocation at the cost of epithelial destruction in experimental shigellosis. Infect Immun 1999; 67:1471-1480.
140. Sansonetti PJ, Arondel J. Construction and evaluation of a double mutant of Shigella flexneri as a candidate for oral vaccination against shigellosis. Vaccine 1989; 7:443-450.
141. Conlan JW. Critical role for neutrophils in host defense against experimental systemic infections of mice by Listeria monocytogenes. Infect Immun 1997; 65:630-635.
142. Czuprynski CJ, Campbell PA, Henson PM. Killing of Listeria monocytogenes by human neutrophils and monocytes, but not by monocyte-derived macrophages. J Reticuloendothel Soc 1983; 34:29-44.
143. Czuprynski CJ, Henson PM, Campbell PA. Killing of Listeria monocytogenes by inflammatory neutrophils and mononuclear phagocytes from immune and nonimmune mice. J Leukoc Biol 1984; 35:193-208.
144. Lowell GH, MacDermott RP, Summers PL, Reeder AA, Bertovich MJ, Formal B. Antibody-dependent cell-mediated antibacterial activity: NK, lymphocytes, monocytes, and granulocytes are effective against Shigella. J Immunol 1980; 125:2778-2784.
145. Mandic-Muleg I, Weiss J, Zychlinsky A. Shigella flexneri is trapped in polymorphonuclear leukocyte vacuoles and efficiently killed. Infect Immun 1997; 65:110-115.
146. Weinrauch Y, Drugan D, Shapiro SD, Weiss J, Zychlinsky A. Neutrophil elastase targets virulence factors of enterobacteria. Nature 2002; 417:91-94.
147. Hathaway LJ, Griffin G, Sansonetti PJ, Edgeworth JD. Human monocytes kill Shigella flexneri but then die by apoptosis associated with suppression of proinflammatory cytokine production. Infect Immun 2002; 70:3833-3842.
148. Sabroe I, Jones EC, Usher LR, Whyte MK, Dower SK. Toll-like receptor (TLR)2 and TLR4 in human peripheral blood granulocytes: a critical role for monocytes in leukocyte lipopolysaccharide responses. J Immunol 2002; 168:4701-4710.
149. Raqib R, Ljungdahl A, Lindberg AA, Andersson U, Andersson J. Local entrapment of interferon gamma in the recovery from Shigella dysenteriae type 1 infection. Gut 1996; 38:328-336.
150. Raqib R, Ljungdahl A, Lindberg AA, Wretlind B, Andersson U, Andersson J. Dissociation between cytokine mRNA expression and protein production in shigellosis. Eur J Immunol 1996; 26:1130-1138.
151. Raqib R, Gustafsson A, Andersson J, Bakhiet M. A systemic downregulation of gamma interferon production is associated with acute shigellosis. Infect Immun 1997; 65:5338-5341.
152. Niesel DW, Hess CB, Cho YJ, Klimpel KD, Klimpel GR. Natural and recombinant interferons inhibit epithelial cell invasion by Shigella spp. Infect Immun 1986; 52:828-833.
153. Way SS, Borczuk AC, Dominitz R, Goldberg MB. An essential role for gamma interferon in innate resistance to Shigella flexneri infection. Infect Immun 1998; 66:1342-1348.
154. LeBarillec K, Phalipon A, DiSanto J. Personal communication.
155. Zwillich SH, Duby AD, Lipsky PE. T-lymphocyte clones responsive to Shigella flexneri. J Clin Microbiol 1989; 27:417-21.
156. Doling A, Starnbach M. Personal communication.
157. Fruh K, Gruhler A, Krishna RM, Schoenhals GJ. A comparison of viral immune escape strategies targeting the MHC class I assembly pathway. Immunol Rev 1999; 168:157-166.
158. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 1996; 272:50-59.
159. Jankovic D, Liu Z, Gause WC. Th1- and Th2-cell commitment during infectious disease: asymmetry in divergent pathways. Trends Immunol 2001; 22(8): 450-457.
160. Kourilsky P, Truffa-Bachi P. Cytokine fields and the polarization of the immune response. Trends Immunol 2001; 22:502-509.
161. Kotloff KL, Hale TL, Barry EM, Sansonetti PJ. Overview of live vaccine strategies against Shigella (in press).
162. Rivenet F, Phalipon A. Personal communication.
163. Gamelas J, Phalipon A. Personal communication.
164. Raqib R, Lindberg AA, Bjork L, Bardhan PK, Wretlind B, Andersson U, Andersson J. Down-regulation of gamma interferon, tumor necrosis factor type I,
165. Cleary TG, Winsor DK, Reich D, Ruiz-Palacios G, Calva JJ. Human milk immunoglobulin A antibodies to Shigella virulence determinants. Infect Immun 1989; 57:1675-1679.
166. Islam D, Wretlin B, Ryd M, Lindberg AA, Christensson B. Immunoglobulin subclass distribution and dynamics of Shigella-specific antibody responses in serum and stool samples in shigellosis. Infect Immun 1995; 63:2045-2061.
167. Keren DF, Kern SE, Bauer DH, Scott PJ, Porter P. Direct demonstration in intestinal secretions of an IgA memory response to orally administered Shigella flexneri antigens. J Immunol 1982; 128:475.
168. Winsor DK, Mathewson JJ, DuPont HL. Comparison of serum and fecal antibody responses of patients with naturally acquired Shigella sonnei infection. J Infect Dis 1988; 158:1108-1112.
169. Dam Cam PT, Pal T, Lindberg AA. Immune response against lipopolysaccharide and invasion plasmid-encoded antigens of shigellae in Vietnamese and Swedish dysenteric patients. J Clin Microbiol 1993; 31:454-457.
170. Oaks EV, Hale TL, Formal SB. Serum immune response to Shigella protein antigens in Rhesus monkeys and humans infected with Shigella spp. Infect Immun 1986; 53:57-63.
171. Oberhelman RA, Kopecko DJ, Salazar-Lindo E, Gotuzzo E, Buysse JM, Venkatesan MM, Yi A, Fernandez-Prada C, Guzman M, Leon-Barua R, Sack RB. Prospective study of systemic and mucosal immune responses in dysenteric patients to specific Shigella invasion plasmid antigens and lipopolysaccharide. Infect Immun 1991; 59:2341-2350.
172. Van de Verg L, Herrington DA, Boslego J, Lindberg AA, Levine MM. Age-specific prevalence of serum antibodies to the invasion plasmid and polysaccharide of Shigella species in Chilean and North-American populations. J Infect Dis 1992; 166:158-161.
173. DuPont HL, Hornick RB, Synder MJ, Libonati JP, Formal SB, Gangarosa EJ. Immunity to shigellosis. II. Protection induced by oral live vaccine or primary infection. J Infect Dis 1972; 125:12.
174. Formal SB, Oaks EV, Olsen RE, Wingfield-Eggleston M, Snoy PJ, Cogan JP. Effect of prior infection with virulent Shigella flexneri 2a on the resistance of monkeys to subsequent infection with Shigella sonnel. J Infect Dis 1991; 164:533-537.
175. Mel DM, Arsic BL, Nikolic BD, Radovanovic ML. Studies on vaccination against bacillary dysentery. IV. Oral immunization with live monotypic and combined vaccines. Bull WHO 1968; 39:375-380.
176. Kofloff KL, Nataro JP, Losonsky GA, Wasserman SS, Hale TL, Taylor DN, Sadoff JC, Levine MM. A modified Shigella volunteers challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine 1995; 13:1488-1494.
177. Mel DM, Terzin AL, Vuksic L. Studies on vaccination against bacillary dysentery. 3. Effective oral immunization against Shigella flexneri 2a in a field trial. Bull WHO 1965; 32:647-655.
178. Formal SB, Kent TH, May HC, Palmer A, Falkow S, LaBrec EH. Protection of monkeys against experimental shigellosis with a living attenuated oral polyvalent dysentery vaccine. J Bacteriol 1966; 92:17-22.
179. Ferreccio C, Prado V, Ojeda A, Cayazzo M, Abrego P, Guers L, Levine MM. Epidemiologic patterns of acute diarrhea and endemic Shigella infections in a poor periurban setting in Santiago, Chile. Am J Epidemiol 1991; 134:614-627.
180. Herrington DA, Van de Verg L, Formal SB, Hale TL, Tall BD, Cryz SJ, Tramont EC, Levine MM. Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine 1990; 8:353-357.
181. Mel DM, Gangarosa EJ, Radovanovic ML, Arsic BL, Litvinjenko S. Studies on vaccination against bacillary dysentery. 6. Protection of children by oral immunization with streptomycin-dependant Shigella strains. Bull WHO 1971; 45:457-464.
182. Tacket CO, Binion SB, Bostwick E, Losonsky GA, Roy MJ, Edelman R. Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge. Am J Trop Med Hyg 1992; 47:276-283.
183. Clemens JD, Stanton B, Stoll B, Shahid NS, Banu H, Chowdhury AK. Breast feeding as a determinant of severity in shigellosis. Evidence for protection throughout the first three years of life in Bangladeshi children. Am J Epidemiol 1986; 123:710-720.
184. Formal SB, Maenza RM, Austin S, LaBrec EH. Failure of parenteral vaccines to protect monkeys against experimental shigellosis. Proc Soc Exp Biol Med 1967; 125:347.
185. Higgins AR, Floyd TM, Kader MA. Studies in shigellosis. III. A controlled evaluation of a monovalent Shigella vaccine in a highly endemic environment. Am J Trop Med Hyg 1955; 4:281-288.
186. Cohen D, Green MS, Block C, Rouach T, Ofek T. Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population. J Infect Dis 1988; 157:1068.
187. Cohen D, Green MS, Block C, Slepon R, Ofek I. A prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis. J Clin Microbiol 1991; 29:386.
188. Passwell JH, Freier S, Shor R, Farzam N, Block C, Lison M, Shiff E, Ashkenazi S. Shigella lipopolysaccharide antibodies in pediatric populations. Pediatr Infect Dis J 1995; 14:859.
189. Van de Verg L, Herrington DA, Boslego J, Lindberg AA, Levine MM. Age-specific prevalence of serum antibodies to the invasion plasmid and polysaccharide of Shigella species in Chilean and North-American populations. J Infect Dis 1992; 166:158-161.
190. Cohen D, Ashkenazi S, Green MS, Gdalevich M, Robin G, Slepon R, Yavzori M, Orr N, Block C, Ashkenazi I, Shemer J, Taylor DN, Hale TL, Sadoff JC, Pavliakova D, Schneerson R, Robbins JB. Double-blind vaccine-controlled randomized efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet 1997; 349:155.
191. Phalipon A, Costachel C, Thuizat A, Nato F, Vullicz-LeNormand B, Marcel-Peyre V, Sansonetti PJ, Mulard L, Structural and immunochemical characterization of serotype-specific protective epitopes carried by the O-Ag of Shigella flexneri serotype 2a lipopolysaccharide. Submitted.
192. Rasolofo-Razanamparany V, Cassel-Beraud AM, Roux J, Sansonetti PJ, Phalipon A. Predominance of serotype-specific mucosal antibody response in Shigella flexneri-infected humans living in an area of endemicity. Infect Immun 2001; 69:5230-5234.
193. Van de Verg LL, Bendiuk NO, Kotloff K, Marsh MM, Ruckert JL, Puryear JL, Taylor DN, Hartman AB. Cross-reactivity of Shigella flexneri 2a O antigen antibodies following immunization or infection. Vaccine 1996; 14:1062-1068.
194. Bingrui W. Study on the effect of oral immunization of T32-Istrati strain against bacillary dysentery in field trials. Arch Roum Pathol Exp Microbiol 1984; 43:285-289.
195. Karnell A, Sweiha H, Lindberg AA. Auxotrophic live oral Shigella flexneri vaccine protects monkeys against challenge with S. flexneri of different serotypes. Vaccine 1992; 10:167-174.
196. Noriega FR, Liao FM, Maneval DR, Ren S, Formal SB, Levine MM. Strategy for cross-protection among Shigella flexneri serotypes. Infect Immun 1999; 67: 782-788.
197. Sasakawa C, Adler B, Tobe T, Okada N, Nagai S, Komatsu K, Yoshikawa M. Functional organization and nucleotide sequence of virulence Region-2 on the large virulence plasmid in Shigella flexneri 2a. Mol Microbiol 1989; 3:1191-1201.
198. Phalipon A, Arondel J, Nato F, Rouyre S, Mazie JC, Sansonetti PJ. Identification and characterization of B-cell epitopes of IpaC, an invasion-associated protein of Shigella flexneri. Infect Immun 1992; 60: 1919-1926.
199. Barzu S, Nato F, Rouyre S, Mazie JC, Sansonetti P, Phalipon A. Characterization of B-cell epitopes on IpaB, an invasion-associated antigen of Shigella flexneri: identification of an immunodominant domain recognized during natural infection. Infect Immun 1993; 61:3825-3831.
200. Menard R, Sansonetti P, Parsot C. The secretion of the Shigella flexneri Ipa invasins is activated by epithelial cells and controlled by IpaB and IpaD. EMBO J 1994; 13:5293-5302.
201. Russell MW, Kilian M, Lamm ME. Biological activities of IgA. In: Ogra PL, editor. Mucosal Immunology, 2nd ed. San Diego: Academic Press, 1999: 225-240.
202. Macpherson AJ, Gatto D, Sainsbury E, Harriman GR, Hengartner H, Zinkernagel RM. A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science. 2000; 288: 2222-2226.
203. Mostov KE. Transepithelial transport of immunoglobulins. Annu Rev Immunol 1994; 12:63-84.
204. Mestecky J, McGhee JR. Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response. Adv Immunol 1987; 40:153-245.
205. Kraehenbuhl JP, Neutra M. Molecular and cellular basis of immune protection of mucosal surfaces. Physiol Rev 1992; 72:853-879.
206. Brandtzaeg P. History of oral tolerance and mucosal immunity Ann N Y Acad Sci 1996; 778:1-27.
207. Corthesy B, Kraehenbuhl JP. Antibody-mediated protection of mucosal surfaces. Curr Top Microbiol Immunol 1999; 236:93-111.
208. Mazanec MB, Nedrud JG, Kaetzel CS, Lamm ME. A three-tiered view of the role of IgA in mucosal defense. Immunol Today 1993; 14:430-435.
209. Robinson JK, Blanchard TG, Levine AD. Emancipator SN, Lamm ME. A mucosal IgA-mediated excretory immune system in vivo. J Immunol 2001; 166: 3688-3692.
210. Fujioka H, Emancipator SN, Aikawa M, Huang DS, Blatnik F, Karban T, DeFife K, Mazanec MB. Immunocytochemical colocalization of specific immunoglobulin A with Sendai virus protein in infected polarized epithelium. J Exp Med. 1998; 188: 1223-1239.
211. Lindh E. Increased resistance of immunoglobulin A dimers to proteolytic degradation after binding of secretory component. J Immunol 1975; 114:284-286.
212. Crottet P, Corthesy B. Secretory component delays the conversion of secretory IgA into antigen-binding competent F(ab′)2: a possible implication for mucosal defense. J Immunol 1998; 16:5445-5453.
213. Crottet P, Cottet S, Corthesy B. Expression, purification and biochemical characterization of recombinant murine secretory component: a novel tool in mucosal immunology. Biochem J 1999; 341:299-306.
214. Phalipon A, Cardona A, Kraehenbuhl JP, Edelman L, Sansonetti PJ, Corthesy B. Secretory component: a new role in secretory IgA-mediated immune exclusion in vivo. Immunity. 2002; 17:107-115.
215. Fernandez MI, Pedron T, Tournebize R, Olivo-Marin JC, Sansonetti PJ, Phalipon A. Anti-inflammatory role for intracellular dimeric immunoglobulin A by neutralization of lipopolysaccharide in epithelial cells. Immunity 2003; 18:739-769.
216. Heumann D, Roger T. Initial responses to endotoxins and Gram-negative bacteria. Clin Chim Acta 2002; 323(1-2):59-72.
217. Hornef MW, Frisan T, Vandewalle A, Normark S, Richter-Dahlfors A. Toll-like receptor 4 resides in the Golgi apparatus and colocalizes with internalized lipopolysaccharide in intestinal epithelial cells. J Exp Med. 2002; 195:559-570.
218. Apodaca G, Katz LA, Mostov KE. Receptor-mediated transcytosis of IgA in MDCK cells is via apical recycling endosomes. J Cell Biol 1994; 125:67-86.
219. Macpherson AJ, Hunziker L, McCoy K, Lamarre A. IgA responses in the intestinal mucosa against pathogenic and non-pathogenic microorganisms. Microbes Infect 2001; 3:1021-1035.
220. Mel DM, Papo RG, Terzin AL, Vuksic L. Studies on vaccination against bacillary dysentery. II. Safety tests and reactogenicity studies on a live dysentery vaccine intended for use in field trials. Bull WHO 1965; 32: 637-645.
221. Meitert T, Pencu E, Ciudin L, Tonciu M. Vaccine strain Shiffella flexneri T32-Istrati. Studies in animals and in volunteers. Antidysentery immunoprophylaxis and immunotherapy by live vaccine Vadizen (Sh. flexneri T32-Istrati). Arch Roum Pathol Exp Microbiol 1984; 43:251-278.
222. Xie G, Wang BR, Wang FL. Study of the 140 Md plasmid of T32-Istrati vacine strain. J Chin Microbiol Immunol 1989; 9:288-291.
223. Barzu S, Fontaine A, Sansonetti P, Phalipon A. Induction of a local anti-IpaC antibody response in mice by use of a Shigella flexneri 2a vacine candidate: implications for use of IpaC as a protein carrier. Infect Immun 1996; 64:1190-1196.
224. Coster TS, Hoge CW, VanDeVerg LL, Hartman AB, Oaks EV, Venkatesan MM, Cohen D, Robin G, Fontaine-Thompson A, Sansonetti PJ, Hale TL. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun 1999; 67: 3437-3443.
225. Bernardini ML, Arondel J, Martini I, Aidara A, Sansonetti PJ. Pasameters underlying successful protection with live attenuated mutants in experimental shigellosis. Infect Immun 2001; 69:1072-1083.
226. D'Hauteville H, Khan S, Maskell DJ, Kussak A, Weintraub A, Mathison J, Ulevitch RJ, Wuscher N, Parsot C, Sansonetti PJ. Two msbB genes encoding maximal acylation of lipid A are required for invasive Shigella flexneri to mediate inflammatory rupture and destruction of the intestinal epithelium. J Immunol 2002; 168:5240-5251.
227. Nodega FR, Losonsky G, Wang JY, Formal SB, Levine MM. Further characterization of delta aroA delta virG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli. Infect Immun 1996; 64:23-27.
228. Loy AL, Allison G, Arias CF, Verma NK. Immune response to rotavirus VP4 expressed in an attenuated strain of Shigella flexneri. FEMS Immunol Med Microbiol 1999; 25:283-288.
229. Barzu S, Arondel J, Guillot S, Sansonetti PJ, Phalipon A. Immunogenicity of IpaC-hybrid proteins expressed in the Shigella flexneri 2a vaccine candidate SC602. Infect Immun 1998; 66:77-82.
230. Altboum Z, Barry EM, Losonsky G, Galen JE, Levine MM. Attenuated Shigella flexneri 2a Delta guaBA strain CVD 1204 expressing enterotoxigenic Escherichia coli (ETEC) CS2 and CS3 fimbriae as a live mucosal vaccine against Shigella and ETEC infection. Infect Immun 2001; 69:3150-3158.
231. Koprowski H II, Levine MM, Anderson RJ, Losonsky G, Pizza M, Barry EM. Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli. Infect Immun 2000; 68:4884-4892.
232. Galen JE, Nair J, Wang JY, Wasserman SS, Tanner MK, Sztein MB, Levine MM. Optimization of plasmid maintenance in the attenuated live vector vaccine strain Salmonella typhi CVD 908-htrA. Infect Immun 1999; 67:6424-6433.
233. Anderson RJ, Pasetti MF, Sztein MB, Levine MM, Noriega FR. DeltaguaBA attenuated Shigella flexneri 2a strain CVD 1204 as a Shigella vaccine and as a live mucosal delivery system for fragment C of tetanus toxin. Vaccine 2000; 18:2193-2202.
234. Fennelly GJ, Khan SA, Abadi MA, Wild TF, Bloom BR. Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella flexneri vector. J Immunol 1999; 162:1603-1610.
235. Shata MT, Hone DM. Vaccination with a Shigella DNA vaccine vector induces antigen-specific CD8(+) T cells and antiviral protective immunity. J Virol 2001; 75:9665-9670.
236. Robbins JB, Chu C, Watson DC, Szu SC, Daniels EM, Lowe CU, Schneerson R. O-specific side-chain toxin-protein conjugates as parenteral vaccines for the prevention of shigellosis and related diseases. Rev Infect Dis 1991; 13(Suppl 4):S362-365.
237. Taylor DN, Trofa AC, Sadoff J, Chu C, Bryla D, Shiloach J, Cohen D, Ashkenazi S, Lerman Y, Egan W et al. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids. Infect Immun 1993; 61(9):3678-3687.
238. Levenson VI, Egorova TP, Belkin ZP, Fedosova VG, Subbotina JL, Rukhadze EZ, Dzhikidze EK, Stassilevich ZK. Protective ribosomal preparation from Shigella sonnei as a parenteral candidate vaccine. Infect Immun 1991; 59:3610-3618.
239. Orr N, Robin G, Cohen D, Arnon R, Lowell GH. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosomelipopolysaccharide vaccines in animal models. Infect Immun 1993; 61:2390-2395.
240. Lowell GH. Proteosomes for improved nasal, oral, or injectable vaccines. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, editors. New Generation Vaccines, 2nd ed. New York: Marcel Dekker, 1997: 193-206.
241. Cohen D, Ashkenazi S, Green M, Lerman Y, Slepon R, Robin G, Orr N, Taylor DN, Sadoff JC, Chu C, Shiloach J, Schneerson R, Robbins JB. Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers. Infect Immun 1996; 64:4074-4077.
242. Robin G, Keisari Y, Slepon R, Ashkenazi S, Cohen D. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines. Vaccine 1999; 17: 3109-3115.
243. Ashkenazi S, Passwell JH, Harlev E, Miron D, Dagan R, Farzan N, Ramon R, Majadly F, Bryla DA, Karpas AB, Robbins JB, Schneerson R. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children. J Infect Dis 1999; 179:1565-1568.
244. Passwell JH, Harlev E, Ashkenazi S, Chu C, Miron D, Ramon R, Farzan N, Shiloach J, Bryla DA, Majadly F, Roberson R, Robbins JB, Schneerson R. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel. Infect Immun 2001; 69:1351-1357.
245. Pavliak V, Nashed EM, Pozsgay V, Kovac P, Karpas A, Chu C, Schneerson R, Robbins JB, Glaudemans CP. Binding of the O-antigen of Shigella dysenteriae type 1 and 26 related synthetic fragments to a monoclonal IgM antibody. J Biol Chem 1993; 268:25797-25802.
246. Falt IC, Lindberg AA. Epitope mapping of six monoclonal antibodies recognizing the Shigella dysenteriae type 1 O-antigenic repeating unit expressed in Escherichia coli K-12. Microb Pathog. 1994; 16:27-41.
247. Toth A, Medgyes A, Bajza I, Liptak A, Batta G, Kontrohr T, Peterffy K, Pozsgay V. Synthesis of the repeating unit of the O-specific polysaccharide of Shigella sonnei and quantitation of its serologic activity. Bioorg Med Chem Lett 2000; 10:19-21.
248. Vyas NK, Vyas MN, Chervenak MC, Johnson MA, Pinto BM, Bundle DR, Quiocho FA. Molecular recognition of oligosaccharide epitopes by a monoclonal Fab specific for Shigella flexneri Y lipopolysaccharide: X-ray structures and thermodynamics. Biochemistry. 2002; 41:13575-13586.
249. Clement NIJ, Mulard L, Delepierre M, Phalipon A. Personal communication.
250. Mulard L, Phalipon A. Personal communication.
251. Pozsgay V, Chu C, Pannell L, Wolfe J, Robbins JB, Schneerson R. Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1. Proc Natl Acad Sci U S A 1999; 96:5194-5197.
252. Harris SL, Craig L, Mehroke JS, Rashed M, Zwick MB, Kenar K, Toone EJ, Greenspan N, Auzanneau FI, Marino-Albernas JR, Pinto BM, Scott JK. Exploring the basis of peptide-carbohydrate cross-reactivity: evidence for discrimination by peptides between closely related anti-carbohydrate antibodies. Proc Natl Acad Sci U S A. 1997; 94:2454-2459.
253. Phalipon A, Folgori A, Arondel J, Sgaramella G, Fortugno P, Cortese R, Sansonetti PJ, Felici F. Induction of anti-carbohydrate antibodies by phage library-selected peptide mimics. Eur J Immunol 1997; 27: 2620-2625.
254. Phalipon A, Felici F. Personal communication.
255. Cooper ML, Tepper J, Keller HM. Studies in dysentery vaccination. VI. Primary vaccination of children with polyvalent vaccines of Shigella. J Immunol 1949; 61:209-219.
256. Mel DM, Gangarosa EJ, Radovanovic ML, Arsic BL, Litvinjenko S. Studies on vaccination against bacillary dysentery. VI. Protection of children by oral immunization with streptomycin-dependent Shigella strains. Bull WHO 1971; 45:457-464.